Anti-Kv1.3 antibodies, and methods of production and use thereof
Inventors
Colussi, Paul A. • BEDNENKO, Janna • Bisharyan, Yelena • Papoyan, Ashot • Cardarelli, Joanna • Clark, Theodore G. • Kahn, Douglas • Mariën, Lore • Van Der Woning, Bas • De Haard, Hans • Harriman, William D. • Collarini, Ellen J. • Agrawal, Alka
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11597763-B2
Publication Date
2023-03-07
Expiration Date
Abstract
Anti-Kv1.3 antibodies (mAbs), particularly mAbs that specifically bind to Kv1.3 with high affinity and/or inhibit Kv1.3 function, are disclosed. The amino acid sequences of the CDRs of the light chains and the heavy chains, as well as consensus sequences for these CDRs, of these anti-Kv1.3 mAbs are provided. Additionally, canonical structures for CDRs in the VH and VL regions of anti-Kv1.3 antibodies are provided. The disclosure also provides nucleic acid molecules encoding the anti-Kv1.3 mAbs, expression vectors, host cells, methods for making the anti-Kv1.3 mAbs, and methods for expressing the anti-Kv1.3 mAbs. Finally, methods of using the anti-Kv1.3 mAbs as therapeutics, such as for preventing or treating an autoimmune disorder, are disclosed.
Core Innovation
The disclosed invention provides an antibody that specifically binds to a human Kv1.3 protein. The antibody comprises an immunoglobulin heavy chain and an immunoglobulin light chain, with variable regions defined by CDR regions and associated sequence identifiers.
The heavy chain variable region comprises a CDR1 region, a CDR2 region, and a CDR3 region, and the light chain variable region comprises a CDR1 region, a CDR2 region, and a CDR3 region. The disclosed content further characterizes these CDRs using consensus or canonical CDR motifs and assigned canonical structures, together with light chain VL and heavy chain VH variable-region framework regions.
The invention is directed to functional antibodies that bind to and inhibit Kv1.3 with reported activity and selectivity profiles relative to other Kv channels. Nucleic acids encoding the antibodies, expression constructs, and host cells for producing the antibodies are also disclosed.
Claims Coverage
The provided claim content identifies one independent claim defining an anti-human Kv1.3 binding antibody by specified CDR regions in both light and heavy chain variable regions, using sequence identifiers.
Anti-human Kv1.3 antibody defined by specified light-chain and heavy-chain CDR sequence identifiers
An antibody specifically binds to a human Kv1.3 protein, comprising an immunoglobulin heavy chain variable region with CDR1 region of SEQ ID NO: 169, a CDR2 region of SEQ ID NO: 182, and a CDR3 region of SEQ ID NO: 207, and an immunoglobulin light chain variable region with a CDR1 region of SEQ ID NO: 55, a CDR2 region of SEQ ID NO: 72, and a CDR3 region of SEQ ID NO: 101.
The claim coverage is focused on sequence-ID-defined CDR regions in both light and heavy chain variable regions for an antibody that specifically binds human Kv1.3.
Stated Advantages
The antibodies bind to and inhibit Kv1.3.
Reported activity and selectivity profiles relative to other Kv channels.
Documented Applications
Therapeutic and diagnostic use for autoimmune disorders.
Therapeutic and diagnostic use for graft-versus-host disease (GvHD).
Interested in licensing this patent?